Abstracts tagged "fracture risk and osteoporosis"

Abstract Number: 1795 • 2014 ACR/ARHP Annual Meeting
Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk: Analyses from the Cross-over Group in the Extension of the Denosumab Pivotal Fracture Trial
JP Bilezikian¹, CL Benhamou², CJF Lin³, JP Brown⁴, NS Daizadeh³, PR Ebeling⁵, A Fahrleitner-Pammer⁶, E Franek⁷, N Gilchrist⁸, PD Miller⁹, JA Simon¹⁰, I Valter¹¹, CAF Zerbini¹² and C Libanati³, ¹College of Physicians and Surgeons, Columbia University, New York, NY, ²CHR d'Orléans, Orléans, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁵Monash University, Clayton, Australia, ⁶Medical University, Graz, Austria, ⁷Medical Research Center, Polish Academy of Sciences, Warsaw, Poland, ⁸The Princess Margaret Hospital, Christchurch, New Zealand, ⁹Colorado Center for Bone Research, Lakewood, CO, ¹⁰George Washington University, Washington, DC, ¹¹Center for Clinical and Basic Research, Tallinn, Estonia, ¹²Centro Paulista de Investigação Clinica, São Paulo, Brazil
Background/Purpose: Cortical bone loss is a major determinant of increased fracture risk. Denosumab (DMAb) has been shown to increase BMD at sites of cortical bone,…
Abstract Number: 240 • 2014 ACR/ARHP Annual Meeting
An Observational Study on the Influence of Glucocorticoid Exposure on Bone
Joseph Heath¹, Alexander Oldroyd², Maarten Boers³ and Marwan Bukhari², ¹Faculty of health and medicine, Lancaster University, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Dep of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose It is well known that glucocorticoids are detrimental to bone health and has been postulated that their influence is more than their effect on…
Abstract Number: 231 • 2014 ACR/ARHP Annual Meeting
Factors Predicting Fracture in the over-75s: An Observational Case-Control Study
Christopher Varley¹, James Fowler², Alexander Oldroyd¹ and Marwan Bukhari³, ¹Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ²Faculty of Health and Medicine, Lancaster Univeristy, Lancaster, United Kingdom, ³Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose In the over 75s the diagnosis of osteoporosis may be assumed following a fracture, making the need for a dual energy absorptiometry scan (DEXA)…
Abstract Number: 1230 • 2013 ACR/ARHP Annual Meeting
Analysis Of Fracture Risk Assessment Score (FRAX) Correlation With Bone Mineral Density (BMD) In Males and Post-Menopausal Females
Vikas Majithia¹ and Khush Aujla², ¹Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ²Division of Rheumatology, University of Mississippi School of Medicine, Jackson, MS
Background/Purpose: Fracture Risk Assessment Tool (FRAX) is a useful clinical tool for assessment of fracture risk and a major development in evaluation of osteoporosis. Its…
Abstract Number: 1223 • 2013 ACR/ARHP Annual Meeting
Monitoring Osteoporosis Therapy: Can FRAX Help To Assess Success Or Failure In Achieving Treatment Goals?
Yasser El Miedany¹, Ahmed Elyassaki², Sally Youssef³, Annie Nasr⁴, Mohammed Hegazi⁵ and Ihab Ahmed⁶, ¹Rheumatology, Medway Hospital, Gillingham, United Kingdom, ²Rheumatology and Rehabilitation, Ain Shams University, Cairo, Egypt, ³Rheumatology & Rehabilitation, Ain Shams University, Cairo, Egypt, ⁴Radiology, Ain Shams University, Cairo, Egypt, ⁵Medicine, Al Adan Hospital, Kuwait, Kuwait, ⁶Medicine, Cairo University, Cairo, Egypt
Background/Purpose: 1. To determine whether FRAX can be used for monitoring patients receiving osteoporosis therapy and its clinical implications 2. Study the correlation between the…
Abstract Number: 1225 • 2013 ACR/ARHP Annual Meeting
FRAX 10-Year Fracture Risk In Women With a Fracture Of The Distal Forearm: Agreement Between Assessments With and Without Bone Mineral Density and Influence Of Measurement Side In Individual Patients
Emilie Egsmose¹, Mette Birkvig², Thora Buhl³ and Ole Rintek Madsen³, ¹Copenhagen University Hospital Hvidovre, Copenhagen, Denmark, ²Osteoporosis Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ³Copenhagen University Hospital Gentofte, Copenhagen, Denmark
Background/Purpose: The FRAX® tool has been developed by WHO to evaluate fracture (Fx) risk of patients. It is based on individual patient models that integrate…
Abstract Number: 864 • 2013 ACR/ARHP Annual Meeting
Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension
Jonathan D. Adachi¹, Serge Ferrari², Carol Zapalowski³, Paul D. Miller⁴, Jean-Yves Reginster⁵, Ove Törring⁶, Nadia Daizadeh³, Andrea Wang³, Cynthia O'Malley⁷, Rachel B. Wagman³ and E. Michael Lewiecki⁸, ¹McMaster University, Hamilton, ON, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³Amgen Inc., Thousand Oaks, CA, ⁴Colorado Center for Bone Research, Lakewood, CO, ⁵University of Liège, Liège, Belgium, ⁶Karolinska Institutet, Södersjukhuset, Stockholm, Sweden, ⁷Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Further Reduction in Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With up to 7 Years in the FREEDOM ExtensionBackground/Purpose: Some…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].